Cargando…
In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms
BACKGROUND: Rifabutin, an oral drug approved to treat Mycobacterium avium infections, demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium enabled by rifabutin cellular uptake through the siderophore receptor FhuE. OBJECTIVES: To determine rifabutin in vitro activi...
Autores principales: | Trebosc, Vincent, Schellhorn, Birgit, Schill, Julian, Lucchini, Valentina, Bühler, Jacqueline, Bourotte, Marilyne, Butcher, Jonathan J, Gitzinger, Marc, Lociuro, Sergio, Kemmer, Christian, Dale, Glenn E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662187/ https://www.ncbi.nlm.nih.gov/pubmed/32869081 http://dx.doi.org/10.1093/jac/dkaa370 |
Ejemplares similares
-
A Nutrient-limited Screen Unmasks Rifabutin Hyperactivity for XDR Acinetobacter baumannii
por: Luna, B., et al.
Publicado: (2020) -
Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates
por: Trebosc, Vincent, et al.
Publicado: (2019) -
Targeting virulence regulation to disarm Acinetobacter baumannii pathogenesis
por: Trebosc, Vincent, et al.
Publicado: (2022) -
Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii
por: Cheng, Jiaqi, et al.
Publicado: (2021) -
Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)